vs
Side-by-side financial comparison of Cue Biopharma, Inc. (CUE) and Hyperscale Data, Inc. (GPUS). Click either name above to swap in a different company.
Hyperscale Data, Inc. is the larger business by last-quarter revenue ($26.9M vs $21.9M, roughly 1.2× Cue Biopharma, Inc.). Cue Biopharma, Inc. runs the higher net margin — 7.2% vs -112.0%, a 119.2% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs 38.4%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs -16.3%).
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
Hyperscale Data, Inc. provides GPU-accelerated computing infrastructure and cloud solutions tailored for AI development, big data processing, and high-performance computing workloads. It primarily serves AI startups, large technology firms, and cloud service providers across North America and the Asia-Pacific region, delivering scalable, high-efficiency computing resources to support complex data processing needs.
CUE vs GPUS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.9M | $26.9M |
| Net Profit | $1.6M | $-30.1M |
| Gross Margin | — | 14.5% |
| Operating Margin | 9.0% | -117.8% |
| Net Margin | 7.2% | -112.0% |
| Revenue YoY | 1292.3% | 38.4% |
| Net Profit YoY | 116.7% | -6670.3% |
| EPS (diluted) | $0.05 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.9M | $26.9M | ||
| Q3 25 | $2.1M | $24.3M | ||
| Q2 25 | $3.0M | $25.9M | ||
| Q1 25 | $421.0K | $25.0M | ||
| Q4 24 | $1.6M | $19.4M | ||
| Q3 24 | $3.3M | $31.1M | ||
| Q2 24 | $2.7M | $17.8M | ||
| Q1 24 | $1.7M | $38.4M |
| Q4 25 | $1.6M | $-30.1M | ||
| Q3 25 | $-7.4M | $-13.0M | ||
| Q2 25 | $-8.5M | $-19.1M | ||
| Q1 25 | $-12.3M | $-4.2M | ||
| Q4 24 | — | $-445.0K | ||
| Q3 24 | $-8.7M | $-25.5M | ||
| Q2 24 | $-10.2M | $-33.9M | ||
| Q1 24 | $-12.3M | $3.7M |
| Q4 25 | — | 14.5% | ||
| Q3 25 | — | 25.8% | ||
| Q2 25 | — | 23.7% | ||
| Q1 25 | — | 21.1% | ||
| Q4 24 | — | 6.5% | ||
| Q3 24 | — | 27.5% | ||
| Q2 24 | — | -21.3% | ||
| Q1 24 | — | 47.4% |
| Q4 25 | 9.0% | -117.8% | ||
| Q3 25 | -353.4% | -57.8% | ||
| Q2 25 | -292.3% | -39.2% | ||
| Q1 25 | -2921.4% | -25.5% | ||
| Q4 24 | — | -46.8% | ||
| Q3 24 | -264.2% | -79.2% | ||
| Q2 24 | -390.6% | -151.4% | ||
| Q1 24 | -737.8% | 9.5% |
| Q4 25 | 7.2% | -112.0% | ||
| Q3 25 | -346.6% | -53.5% | ||
| Q2 25 | -287.1% | -73.7% | ||
| Q1 25 | -2911.4% | -16.8% | ||
| Q4 24 | — | -2.3% | ||
| Q3 24 | -259.6% | -82.3% | ||
| Q2 24 | -382.7% | -190.7% | ||
| Q1 24 | -719.1% | 9.7% |
| Q4 25 | $0.05 | — | ||
| Q3 25 | $-0.07 | $-0.39 | ||
| Q2 25 | $-0.09 | $-2.66 | ||
| Q1 25 | $-0.17 | — | ||
| Q4 24 | — | $-8.78 | ||
| Q3 24 | $-0.17 | $-24.82 | ||
| Q2 24 | $-0.20 | $-37.81 | ||
| Q1 24 | $-0.25 | $3.32 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.1M | $13.1M |
| Total DebtLower is stronger | — | $83.1M |
| Stockholders' EquityBook value | $26.4M | $119.8M |
| Total Assets | $42.2M | $313.7M |
| Debt / EquityLower = less leverage | — | 0.69× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.1M | $13.1M | ||
| Q3 25 | $11.7M | $24.8M | ||
| Q2 25 | $27.5M | $5.9M | ||
| Q1 25 | $13.1M | $4.2M | ||
| Q4 24 | $22.5M | $4.5M | ||
| Q3 24 | $32.4M | $7.9M | ||
| Q2 24 | $30.0M | $9.6M | ||
| Q1 24 | $41.0M | $18.9M |
| Q4 25 | — | $83.1M | ||
| Q3 25 | — | $80.0M | ||
| Q2 25 | — | $88.5M | ||
| Q1 25 | — | $92.8M | ||
| Q4 24 | — | $96.7M | ||
| Q3 24 | $1.0M | $104.8M | ||
| Q2 24 | $2.0M | $106.8M | ||
| Q1 24 | $3.0M | $30.0M |
| Q4 25 | $26.4M | $119.8M | ||
| Q3 25 | $13.2M | $55.9M | ||
| Q2 25 | $18.2M | $5.5M | ||
| Q1 25 | $6.6M | $6.3M | ||
| Q4 24 | $17.5M | $8.6M | ||
| Q3 24 | $25.4M | $2.7M | ||
| Q2 24 | $21.6M | $26.7M | ||
| Q1 24 | $30.0M | $59.0M |
| Q4 25 | $42.2M | $313.7M | ||
| Q3 25 | $31.6M | $242.4M | ||
| Q2 25 | $40.7M | $213.5M | ||
| Q1 25 | $22.3M | $218.5M | ||
| Q4 24 | $32.2M | $220.8M | ||
| Q3 24 | $44.8M | $231.5M | ||
| Q2 24 | $42.3M | $270.8M | ||
| Q1 24 | $54.0M | $299.8M |
| Q4 25 | — | 0.69× | ||
| Q3 25 | — | 1.43× | ||
| Q2 25 | — | 16.06× | ||
| Q1 25 | — | 14.71× | ||
| Q4 24 | — | 11.19× | ||
| Q3 24 | 0.04× | 38.41× | ||
| Q2 24 | 0.09× | 4.00× | ||
| Q1 24 | 0.10× | 0.51× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $-37.7M |
| Free Cash FlowOCF − Capex | — | $-56.2M |
| FCF MarginFCF / Revenue | — | -208.7% |
| Capex IntensityCapex / Revenue | 0.0% | 68.6% |
| Cash ConversionOCF / Net Profit | -0.68× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-87.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.1M | $-37.7M | ||
| Q3 25 | $-9.0M | $-17.8M | ||
| Q2 25 | $-3.4M | $-3.1M | ||
| Q1 25 | $-8.2M | $-4.0M | ||
| Q4 24 | $-36.3M | $-9.2M | ||
| Q3 24 | $-7.5M | $3.7M | ||
| Q2 24 | $-10.0M | $-3.7M | ||
| Q1 24 | $-9.8M | $-10.2M |
| Q4 25 | — | $-56.2M | ||
| Q3 25 | — | $-20.6M | ||
| Q2 25 | $-3.4M | $-3.5M | ||
| Q1 25 | $-8.3M | $-6.8M | ||
| Q4 24 | $-36.4M | $-9.3M | ||
| Q3 24 | $-7.5M | $2.6M | ||
| Q2 24 | $-10.0M | $-5.9M | ||
| Q1 24 | $-9.8M | $-11.6M |
| Q4 25 | — | -208.7% | ||
| Q3 25 | — | -84.5% | ||
| Q2 25 | -116.5% | -13.5% | ||
| Q1 25 | -1976.7% | -27.3% | ||
| Q4 24 | -2309.3% | -47.6% | ||
| Q3 24 | -225.7% | 8.4% | ||
| Q2 24 | -376.2% | -33.4% | ||
| Q1 24 | -573.0% | -30.3% |
| Q4 25 | 0.0% | 68.6% | ||
| Q3 25 | 0.0% | 11.5% | ||
| Q2 25 | 0.9% | 1.5% | ||
| Q1 25 | 35.6% | 11.5% | ||
| Q4 24 | 4.2% | 0.3% | ||
| Q3 24 | 0.0% | 3.6% | ||
| Q2 24 | 0.4% | 12.6% | ||
| Q1 24 | 3.2% | 3.7% |
| Q4 25 | -0.68× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -2.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
GPUS
| Transferred Over Time | $10.4M | 39% |
| Revenue From Mined Crypto Assets At Sentinum Owned And Operated Facilities | $5.8M | 21% |
| Hotel And Real Estate Operations | $4.8M | 18% |
| Other | $4.0M | 15% |
| Turn On Green | $2.0M | 7% |
